UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) | December 21, 2010 |
ENZON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 0-12957 | 22-2372868 |
| (State or other jurisdiction of incorporation) | (Commission File No.) | (IRS Identification No.) |
| 685 Route 202/206, Bridgewater, New Jersey | 08807 |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code | (908) 541-8600 |
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| £ | | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| £ | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| £ | | Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) |
| £ | | Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
On December 21, 2010, Enzon Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the approval by the Company’s board of directors of a stock repurchase program for the repurchase of up to $200 million of the Company’s common stock. There can be no assurance as to the number of shares the Company will repurchase, if any.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description |
| | |
99.1 | Press Release Dated December 21, 2010 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: December 21, 2010
| By: | /s/ Andrew Rackear |
| | Andrew Rackear |
| | | Vice President and General Counsel |
| | |
